Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist, Nadolol, In Smoking Cessation of Patients With Pre-existing COPD
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2017
Price : $35 *
At a glance
- Drugs Nadolol (Primary)
- Indications Chronic obstructive pulmonary disease; Smoking withdrawal
- Focus Therapeutic Use
- Sponsors Invion
- 05 Oct 2015 Results published in an Invion media release.
- 01 Sep 2015 According to an Invion media release, data from this trial is expected to be reported in the third quarter of 2015.
- 18 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.